AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03039114
Drug: Gazyvaro
RxNorm normalized name: Gazyva
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
Trial: NCT02498002
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
Trial: NCT02553772
Drug: Carboxymethylcellulose Based Eye Drop
RxNorm normalized name: carboxymethylcellulose Ophthalmic Solution [EyS Dry Eye]
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
Trial: NCT02553772
Drug: Carboxymethylcellulose Sodium 0.5%
RxNorm normalized name: Carboxymethylcellulose Sodium 0.5% Lubricant Eye Drops
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
Trial: NCT02297997
Drug: cetylpyridinium chloride
RxNorm normalized name: Cetylpyridinium Chloride
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
Trial: NCT00491868
Drug: R744
RxNorm normalized name: Remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
Trial: NCT00491868
Drug: R744
RxNorm normalized name: Remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
Trial: NCT00491868
Drug: rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
Trial: NCT00491868
Drug: rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
Trial: NCT02273388
Drug: BI 6727
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 6727
Trial: NCT02189837
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by mouth
Trial: NCT02189837
Drug: Placebo to Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous injection
Trial: NCT02189837
Drug: Placebo to Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by mouth
Trial: NCT04991207
Drug: bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tracleer (bosentan) 125 mg film coated tablets
Trial: NCT02304393
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Trial: NCT02304393
Drug: Selicrelumab
RxNorm normalized name: Selicrelumab
DrugBank: Selicrelumab (DB14958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Trial: NCT04215237
Drug: Atorvastatin 20 Mg Oral Tablet
RxNorm normalized name: atorvastatin 20 mg oral tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg oral once a day
Trial: NCT01288404
Drug: Fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
Trial: NCT01288404
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subconjunctival bevacizumab 1.25 mg/0.05mL
Trial: NCT01288404
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subconjunctival bevacizumab 2.5 mg/0.1mL
Trial: NCT01288404
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subconjunctival bevacizumab 3.75 mg/0.15mL
Trial: NCT00059592
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00165763
Drug: donepezil hydrochloride (Aricept)
RxNorm normalized name: donepezil hydrochloride Oral Tablet [Aricept]
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
Trial: NCT02715011
Drug: JNJ-63709178
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-63709178 in Part 1 and Part 2.
Trial: NCT04359147
Drug: Yohimbine
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Trial: NCT00003080
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003080
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003080
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003080
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00091611
Drug: IL-2 (interleukin-2)
RxNorm normalized name: Ile
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00091611
Drug: OKT3
RxNorm normalized name: Humanized OKT3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00091611
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02922127
Drug: Ulipristal Acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily use of Ulipristal Acetate
Trial: NCT02922127
Drug: Combined Oral Contraceptive Pill
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of Oral Contraceptive Pill
Trial: NCT01326845
Drug: Deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03902665
Drug: Up-front allogeneic hematopoietic stem cell transplantation (HSCT)
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only.
Trial: NCT00488189
Drug: Tazocin (pipercillin/tazobactam)
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: over 50% third generation cephalosporin should be replaced by Pip/Taz
Trial: NCT03759392
Drug: Omecamtiv Mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
Trial: NCT04565574
Drug: E7090
RxNorm normalized name: Elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT04565574
Drug: Rabeprazole 20 mg
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
Trial: NCT04565574
Drug: Rifampin 600 mg
RxNorm normalized name: rifampin 600 MG
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
Trial: NCT00967330
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg iv every 2 weeks
Trial: NCT00967330
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 125mg/m2 iv every 2 weeks
Trial: NCT00967330
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
Trial: NCT02456740
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous injection once a month
Trial: NCT04785547
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mcg/m2/day for 28 days
Trial: NCT03817190
Drug: DS107
RxNorm normalized name: Doxylamine Succinate
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DS107 Capsule
Trial: NCT04138498
Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
RxNorm normalized name: dexmethylphenidate 5 mg oral capsule, extended release
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference listed drug (RLD) for comparative BA evaluation
Trial: NCT04138498
Drug: Dexmethylphenidate 6.25 mg Tablet
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental drug for comparative BA evaluation
Trial: NCT04138498
Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
RxNorm normalized name: dexmethylphenidate 40 mg oral capsule, extended release
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference listed drug (RLD) for comparative BA evaluation
Trial: NCT04138498
Drug: Dexmethylphenidate 50 mg Tablet
RxNorm normalized name: dexmethylphenidate Oral Tablet
DrugBank: Dexmethylphenidate (DB06701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental drug for comparative BA evaluation
Trial: NCT03689465
Drug: ATG
RxNorm normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
Trial: NCT03689465
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
Trial: NCT03689465
Drug: Ciclosporin A (CsA)
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
Trial: NCT01379157
Drug: Imipenem
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
Trial: NCT01379157
Drug: Imipenem
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
Trial: NCT01130662
Drug: combination therapy using decitabine and midostaurin
RxNorm normalized name: decitabine, combinations
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle.
Trial: NCT00273988
Drug: nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01937871
Drug: 5 mg Tadalafil
RxNorm normalized name: tadalafil 5 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01937871
Drug: 0.2 mg Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00970593
Drug: OAP-189
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.005 mg in 1 mL TOPICAL LIQUID [Pro Formance Plum Perfection Antibacterial Foam S oap]
DrugBank: Plum (DB10560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
Trial: NCT03719625
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
Trial: NCT00577863
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
Trial: NCT01090414
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib tablets or capsules administered orally
Trial: NCT00074308
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT00356525
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
Trial: NCT00356525
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
Trial: NCT00356525
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
Trial: NCT00356525
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
Trial: NCT02836925
Drug: Ledipasvir+Sofosbuvir
RxNorm normalized name: ledipasvir / sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~* 12 weeks in previously untreated infected patients~* 24 weeks for previously treated patients with uncertain subsequent retreatment options
Trial: NCT02836925
Drug: Sofosbuvir+Velpatasvir
RxNorm normalized name: sofosbuvir / velpatasvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment
Trial: NCT00805324
Drug: Desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desloratadine syrup; 5.0 mL once daily for 28 days
Trial: NCT04647903
Drug: d-amphetamine sulfate
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crushed d-amphetamine sulfate 3x10mg
Trial: NCT03014843
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
Trial: NCT03014843
Drug: Methylnaltrexone Bromide
RxNorm normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
Trial: NCT03295955
Drug: Amoxicillin Clavulanate
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery
Trial: NCT02802813
Drug: Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02802813
Drug: Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04001036
Drug: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One bag for nocturnal (long-dwell) exchange.
Trial: NCT04001036
Drug: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One to three, daily (short-dwell) exchanges
Trial: NCT00200902
Drug: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
Trial: NCT00470535
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00696215
Drug: rasagiline
RxNorm normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mg
Trial: NCT04468685
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interperitoneal administration in the gall bladder bed
Trial: NCT00648778
Drug: Loxapine Succinate Capsules 25 mg
RxNorm normalized name: Loxapine Succinate
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg, single dose fasting
Trial: NCT04238078
Drug: Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill
Trial: NCT01897428
Drug: Test-Bepotastine salicylate 9.64 mg
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01897428
Drug: Reference-bepotastine besilate 10 mg
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no